BioCentury | May 20, 2019
Clinical News
May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular
...active ulcerative colitis. Phase III miss for Ocular's glaucoma therapy Ocular Therapeutix Inc. (NASDAQ:OCUL) said OTX-TP...
...points; the endpoint required significance at all nine. OTX-TP is an intracanalicular insert that delivers sustained-release travoprost...
...1 Brian Moy, Assistant Editor Entyvio, vedolizumab (MLN0002) inclisiran (aln-pcssc, pcsk9si) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Nuplazid, pimavanserin (ACP-103, pimavanserin tartrate) Sustained-release travoprost (OTX-TP) Acadia...
...points; the endpoint required significance at all nine. OTX-TP is an intracanalicular insert that delivers sustained-release travoprost...
...1 Brian Moy, Assistant Editor Entyvio, vedolizumab (MLN0002) inclisiran (aln-pcssc, pcsk9si) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Nuplazid, pimavanserin (ACP-103, pimavanserin tartrate) Sustained-release travoprost (OTX-TP) Acadia...